Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FOMX

Menlo Therapeutics (FOMX) Stock Price, News & Analysis

Menlo Therapeutics logo

About Menlo Therapeutics Stock (NASDAQ:FOMX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$2.99
$2.99
50-Day Range
$2.99
$2.99
52-Week Range
$1.97
$4.84
Volume
N/A
Average Volume
518,350 shs
Market Capitalization
$184.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Remove Ads
Receive FOMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Menlo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOMX Stock News Headlines

Michael J. Fox Foundation taps Palo Alto AI firm
A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
See More Headlines

FOMX Stock Analysis - Frequently Asked Questions

Menlo Therapeutics Inc. (NASDAQ:FOMX) announced its quarterly earnings results on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.07.

Based on aggregate information from My MarketBeat watchlists, some other companies that Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Bristol-Myers Squibb (BMY), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/11/2019
Today
3/11/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medicinals & Botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:FOMX
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.60 million
Price / Cash Flow
N/A
Book Value
$1.70 per share
Price / Book
1.76

Miscellaneous

Free Float
N/A
Market Cap
$184.12 million
Optionable
Optionable
Beta
1.66
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:FOMX) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners